Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4%
Other Routine +

Bausch + Lomb Launches PreserVision AREDS3(TM) Eye Vitamins in the United States

Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

By The Northwire Desk — AI Analysis May 19, 2026 · 07:00 BLCO · 21.98 BAUSCH + LOMB CORPORATION
Executive Summary
  • Bausch + Lomb announced the U.S. launch of PreserVision AREDS3 eye vitamins on May 19, 2026.
  • The new formula combines clinically proven AREDS2 nutrients with a proprietary B-vitamin complex (B1, B2, B3, B5, B6, B7, B9, B12).
  • Designed for individuals in earlier stages of age-related macular degeneration (AMD), expanding the addressable market from 11 million to 28 million patients.
  • Product is available at major national retailers including Amazon, Target, Walgreens, and Walmart.
  • Clinical foundation includes a narrative review synthesizing over 20 human studies involving nearly 30,000 individuals.
  • Company plans for a future long-term clinical trial to evaluate the AREDS3 formulation efficacy.
Material Impact
  • The launch was explicitly anticipated in the November 2025 Investor Day presentation which listed PreserVision AREDS3 as an H1 2026 consumer segment launch.
  • Previous news on April 23, 2026 announced the published review and intent to launch, making this execution rather than new information.
  • Revenue impact is incremental; while it expands the AMD portfolio, supplements face high competition and pricing pressure compared to prescription pharmaceuticals like MIEBO or XIIDRA.
  • No change to full-year guidance was issued with this release; financial targets remain aligned with Q1 2026 raised guidance ($5.42B-$5.52B revenue).
  • The news confirms management is executing on the "Vision '27" transformation plan but does not alter the fundamental investment thesis or risk profile significantly.
BLCO · Price
Company Overview
  • Flagship Projects: MIEBO (dry eye), XIIDRA (lifitegrast ophthalmic solution), enVista IOLs (intraocular lenses), Stellaris Elite Surgical System.
  • Business Segments: Vision Care (Contact Lenses, OTC), Pharmaceuticals (Dry Eye treatments), Surgical (IOLs, Equipment).
  • Pipeline: $7 billion peak-sales pipeline projected across consumer, pharmaceutical, surgical and contact-lens segments through 2031.
  • Key Assets: LUMIFY holds ~70% U.S. redness relief market share; MIEBO and XIIDRA driving pharmaceutical growth phase.
  • Strategic Focus: "Vision '27" initiative targeting margin expansion to ~23% adjusted EBITDA by 2028.
Read the original news release →

More from BAUSCH + LOMB CORPORATION

Jul 01, 2026 · 07:00

Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

Other Jun 01, 2026 · 06:59

Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

Financings May 21, 2026 · 07:15

Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Other May 20, 2026 · 16:49

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

Regulatory May 07, 2026 · 07:00

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

Other May 06, 2026 · 07:15

Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise

Other